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Sepsis is the third leading cause of death in the neonatal population, due to susceptibility
to infection conferred by immaturity of both the innate and adaptive components of the
immune system. Invariant natural killer T (iNKT) cells are specialized adaptive immune
cells that possess important innate-like characteristics and have not yet been well-studied
in septic neonates. We hypothesized that iNKT cells would play an important role in
mediating the neonatal immune response to sepsis. To study this, we subjected 5- to 7day-old neonatal C57BL/6 mice to sepsis by intraperitoneal (i.p.) cecal slurry (CS) injection. Thirty hours prior to or immediately following sepsis induction, pups received i.p.
injection of the iNKT stimulator KRN7000 (KRN, 0.2 µg/g) or vehicle. Ten hours after CS
injection, blood and tissues were collected for various analyses. Thirty-hour pretreatment
with KRN resulted in better outcomes in inflammation, lung injury, and survival, while
immediate treatment with KRN resulted in worse outcomes compared to vehicle treatment. We further analyzed the activation status of neonatal iNKT cells for 30 h after KRN
administration, and showed a peak in frequency of CD69 expression on iNKT cells and
serum IFN-γ levels at 5 and 10 h, respectively. We then used CD1d knockout neonatal
mice to demonstrate that KRN acts through the major histocompatibility complex-like
molecule CD1d to improve outcomes in neonatal sepsis. Finally, we identified that KRN
pretreatment exerts its protective effect by increasing systemic levels of TGF-β1. These
findings support the importance of iNKT cells for prophylactic immunomodulation in
neonates susceptible to sepsis.
Keywords: neonatal sepsis, invariant natural killer T cells, KRN7000, CD1d, inflammation, lung injury, IFN-γ, TGF-β1

INTRODUCTION
Sepsis is defined as a dysregulated host response to infection that results in life-threatening organ dysfunction (1). Sepsis remains a leading cause of morbidity and mortality worldwide, with peak incidences
at the extremes of age. In fact, sepsis is the third leading cause of death during the neonatal period, from
birth to 28 days of life (2–4). The prevalence of sepsis among very low birth weight (<1,500 g) neonates
Abbreviations: ANOVA, analysis of variance; α-GalCer, α-galactosylceramide, (N-[(1 S,2S,3R)-1-[(α-D-galactopyranosyloxy)
methyl]-2,3-dihydroxyheptadecyl]-hexacosanamide); BW, body weight; CS, cecal slurry; DMSO, dimethyl sulfoxide; ELISA,
enzyme-linked immunosorbent assay; FSC, forward scatter; FVD, fixability viability dye; H&E, hematoxylin and eosin;
ILL, innate-like lymphocyte; iNKT, invariant natural killer T; i.p., intraperitoneal; KC, keratinocyte chemoattractant; KRN,
KRN7000, a synthetic α-galactosylceramide analog, ((2 S,3S,4R)-1-O-(α-D-galactopyranosyl)-N-hexacosanoyl-2-amino1,3,4-octadecanetriol); MIP-2, macrophage inflammatory protein-2; SSC, side scatter; TLR, toll-like receptor.
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is considerably high with estimates of 25–30% and mortality
estimates as high as 52% (5). In the United States alone, neonatal
infections account for an estimated 40,000 to 50,000 deaths per year
along with a financial burden of almost $700 million (6).
The immune system serves as the body’s major defense against
infection. However, over-stimulation of immune cells during
sepsis causes hyperinflammation that leads to organ injury and
dysfunction (7). In addition, subsequent immunosuppression
seen in sepsis predisposes patients to the development of secondary infections (8). By better understanding the response profiles
of various immune cells during sepsis, we will be better able to
target their responses and prevent sequelae including end-organ
failure and death. Natural killer T (NKT) cells are members
of the innate-like lymphocyte (ILL) class of immune cells (9).
ILLs are cells that are characterized as members of the adaptive
immune system by virtue of possessing a B or T cell receptor,
but which also possess characteristics that they share with many
cells of the innate immune system (10, 11). These characteristics
make ILLs available as a first line of defense in infection, unlike
conventional cells of the adaptive immune system, which require
recruitment and clonal expansion over the course of days. Given
the immaturity of the innate and adaptive immune responses in
neonatal sepsis, there may be an important role for such cells that
straddle the line between the two conventionally defined systems.
Invariant natural killer T (iNKT) cells are the major subset of
NKT cells and are so named because they possess an invariant
T cell receptor α chain (Vα14Jα18 in mice and Vα24Jα18 in
humans) combined with a limited number of β chains (Vβ8.2,
Vβ7, or Vβ2 in mice and Vβ11 in humans) (12, 13). These cells
require the major histocompatibility complex-like molecule
CD1d for development and respond with specificity to glycolipid
antigens presented by this molecule (14, 15). In adults, iNKT cells
behave in an innate fashion in response to danger signals, increasing in number and rapidly producing a broad range of cytokines,
most notably interferon (IFN)-γ and interleukin (IL)-4, within
minutes to hours of activation (12, 13, 15). iNKT cells may also
be stimulated directly through toll-like receptor (TLR) engagement, leading to enhanced IFN-γ but reduced IL-4 production
(16). Activated iNKT cells affect myriad downstream immune
responses, with direct and/or indirect effects on NK and B cell
activation, T cell activation and differentiation, neutrophil
recruitment, macrophage activation and polarization, and dendritic cell activation and cross-presentation (13).
The first identified lipid antigen of iNKT cells was
α-galactosylceramide (α-GalCer) (13, 17). This discovery paved
the way for the development of α-GalCer-loaded CD1d tetramers,
facilitating the identification of iNKT cells using flow cytometry.
In the same line, KRN7000, a synthetic α-GalCer analog, has been
demonstrated to effectively activate iNKT cells in adult mice, and
it has been reported to have potential therapeutic effects. For
example, administration of α-GalCer after the creation of myocardial infarction in mice leads to an increase in survival rate (18).
KRN7000 has additionally been shown to prevent graft-vs.-host
disease in an adult mouse model (19).
To date, there has been little study of iNKT cells in neonates,
and especially of their role in sepsis. Given our current understanding of the immune response to sepsis, and the capacity of
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adult iNKT cells to effect downstream immune functions, we
hypothesized that iNKT cells would play an important role in
mediating the immune response in neonatal sepsis. In this study,
we employed a polymicrobial sepsis mouse model using intraperitoneal (i.p.) cecal slurry (CS) injection to determine the effect
of activation of iNKT cells by KRN7000 at different time points
on inflammation, lung injury, and survival in neonates. We then
monitored the dynamic change of hepatic iNKT cells in healthy
neonates after stimulation with KRN7000. We further used CD1d
knockout (KO) mice to validate CD1d’s mediation of the effect
of KRN7000. Finally, we used a cytokine array to identify that
transforming growth factor (TGF)-β1 is a downstream product
of iNKT cell activation, and further characterized the effect of
TGF-β1 treatment in septic neonatal mice.

MATERIALS AND METHODS
Experimental Animals

Neonatal mice were defined as those 5–7 days old. C57BL/6 male
and female neonatal mice were obtained from in-house breeder
pairs or from pregnant dams purchased from Charles River
Laboratories (Wilmington, MA, USA). B6.129S6-Del(3Cd1d2CD1d1)1Sbp/J (CD1d KO) breeder pairs were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). A CD1d KO
colony was established and neonatal mice were then obtained
from the in-house breeder pairs. For all experiments pups were
litter- and weight-matched between groups. Neonatal mice were
housed with their mothers and breast-fed ad libitum before and
after all experimental procedures. In-house young adult male and
female C57BL/6 mice (20–25 g) were used for CS preparation. All
experiments were performed in accordance with the guidelines
for the use of experimental animals by NIH (Bethesda, MD,
USA), and were approved by the Institutional Animal Care and
Use Committee of the Feinstein Institute for Medical Research.
All mice were housed in a temperature-controlled room with a
12-h light–dark cycle. For all in vivo experiments, anesthesia was
induced and maintained using inhaled isoflurane.

CS Preparation

Six young adult male and female C57BL/6 mice were euthanized
by CO2 asphyxiation and their cecal contents were harvested. The
cecal contents were weighed and then homogenized through a
70 µm strainer in 5% dextrose in water to create the CS. CS was
then aliquotted and frozen at −80°C until use.

Polymicrobial Sepsis Model
and Survival Studies

The polymicrobial sepsis model was modified as previously
described by Wynn et al. (20). Neonatal mice were anesthetized
using inhaled isoflurane. They were then gently restrained and
CS was injected i.p. at a dose of 0.9 mg/g body weight (BW) for
10-h experiments and 0.175 mg/g BW for survival experiments.
Sham mice received an equivalent volume of normal saline i.p.
For 10-h experiments, neonates were anesthetized by isoflurane
and then euthanized by cardiac puncture. Blood and tissues were
collected and preserved for analysis. For survival studies, mice
2
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were monitored for a period of 7 days and surviving pups were
euthanized by CO2 asphyxiation at the end of the study.

leukemia virus reverse transcriptase (Applied Biosystems, Foster
City, CA, USA). The qPCR reaction was carried out in a 20-µl
final volume containing 0.25 µl each of forward and reverse primers, 2 µl cDNA, 7.5 µl diethyl pyrocarbonate-treated water, and
10 µl Power SYBR Green PCR Master Mix (Applied Biosystems).
An Applied Biosystems StepOnePlus real-time PCR machine was
used for amplification under the thermal cycling profile of 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for
1 min. Mouse β-actin mRNA levels were used for normalization.
Relative expression of mRNA was calculated by the 2−ΔΔCt method,
and results are expressed as fold change in comparison to the
sham group. The sequences for the primers used in this study are
as follows: mouse IL-6 5′-CCGGAGAGGAGACTTCACAG-3′
(forward) and 5′-GGAAATTGGGGTAGGAAGGA-3′ (reverse);
mouse IL-1β 5′-CAGGATGAGGACATGAGCACC-3′ (forward)
and 5′-CTCTGCAGACTCAAACTCCAC-3′ (reverse); mouse
keratinocyte chemoattractant (KC) 5′- GCTGGGATTCACCTCA
AGAA-3′ (forward) and 5′-ACAGGTGCCATCAGAGCAGT-3′
(reverse); mouse macrophage inflammatory protein-2 (MIP-2)
5′-CCCTGGTTCAGAAAATCATCCA-3′ (forward) and 5′-GCT
CCTCCTTTCCAGGTCAGT-3′ (reverse); and mouse β-actin
5′-CGTGAAAAGATGACCCAGATCA-3′ (forward) and 5′-TGG
TACGACCAGAGGCATACAG-3′ (reverse).

Experimental Reagents

The synthetic α-GalCer analog KRN7000 was purchased from
Funakoshi (Tokyo, Japan). KRN was dissolved in dimethyl
sulfoxide (DMSO) at a concentration of 1 mg/ml at 80°C. It was
then aliquotted and stored at −20°C until use. Prior to injection,
the dissolved KRN was diluted in PBS to a final concentration
of 25 µg/ml. Neonatal mice were randomized to receive KRN
(0.2 µg/g BW) or vehicle (2.5% DMSO in PBS) in the same
volume within 1 h after or 30 h prior to CS injection. Lyophilized
carrier-free recombinant mouse TGF-β1 was purchased from
R&D Systems (Minneapolis, MN, USA). TGF-β1 was reconstituted in 4 mM HCl at a concentration of 50 µg/ml. It was then
aliquotted and stored at −20°C until use. Prior to injection the
reconstituted TGF-β1 was diluted in PBS to a final concentration
of 10 µg/ml. Neonatal mice were randomized to receive TGF-β1
(0.05 µg/g BW) or vehicle (PBS containing 0.8 mM HCl) in the
same volume 1 h prior to CS injection.

Flow Cytometry

Whole livers were harvested from neonatal mice and preserved
on ice in RPMI cell culture medium containing 10% FBS, 1%
penicillin–streptomycin, 10 mM HEPES, 2 mM l-glutamine, and
50 µM β-mercaptoethanol. Livers were dissociated and homo
genized by crushing and filtering through a sterile 70-µm nylon
filter. Erythrocytes were then lysed using ammonium-chloridepotassium lysing buffer (Quality Biological, Gaithersburg, MD,
USA). Cells were then washed and resuspended in RPMI cell
culture medium. The isolated cells were first washed with PBS
and stained with Fixability Viability Dye (FVD) eFluor506 (eBioscience, Santa Clara, CA, USA). They were then resuspended
in flow cytometry buffer (PBS containing 2% FBS and 0.1%
sodium azide) and stained with the following fluorescent antibodies: FITC-CD3, APC/Cy7-CD69 (Biolegend, San Diego, CA,
USA) and PE-PBS-57 (α-GalCer)-loaded CD1d tetramer (NIH
Tetramer Core Facility, Atlanta, GA, USA). Cells were acquired
using a BD LSRFortessa flow cytometer (BD Biosciences, San
Jose, CA, USA). Flow cytometry data were analyzed using FlowJo
7.6.5 software (FlowJo LLC, Ashland, OR, USA). On analysis,
whole hepatocyte samples were first gated using forward scatter
(FSC) and side scatter (SSC) characteristics to identify the lymphocyte population. FSC-H vs. FSC-A gating was then used to
exclude doublet cells, and dead cells (FVD eFluor506-positive)
were identified and excluded. The FITC-CD3 and PE-α-GalCerloaded CD1d tetramer double-positive population was identified
as iNKT cells. APC/Cy7-CD69 expression on these cells was
analyzed compared to an unstained negative control.

Measurement of Serum Cytokines

Whole blood samples were allowed to clot for 15–30 min after
collection by cardiac puncture. Serum was then separated by
centrifugation at 3,000 rpm for 10 min at 4°C and stored at −80°C
until use. Serum levels of IL-6, IL-1β, and IFN-γ were measured
using enzyme-linked immunosorbent assay kits specific for these
cytokines according to manufacturer instructions (BD Biosciences).
For the ELISArray, serum samples for each group were pooled
(5–10 per group). A multi-analyte ELISArray for the following
cytokines was carried out per manufacturer instructions: IL-2, IL-4,
IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IL-23, IFN-γ, TNF-α, and
TGF-β1 (QIAGEN, Germantown, MD, USA). In instances in which
serum volumes were insufficient to measure all 12 cytokines, the
IFN-γ well was not used and has been omitted from our analysis.

Histology

Neonatal lung lobes were collected 10 h after CS or sham injection
and stored in 10% formalin prior to fixation in paraffin. They were
subsequently sectioned into 5-µm cuts and stained with hematoxylin and eosin (H&E). Histologic lung injury was assessed in
a blinded fashion using light microscopy evaluation and severity
of injury was scored using a system for the assessment of acute
lung injury in experimental animals outlined by the American
Thoracic Society (21). The weighted score took into account
neutrophil infiltration in the alveolar and interstitial spaces, the
presence of hyaline membranes, the presence of proteinaceous
debris in the airspaces, and the degree of septal thickening.
Twenty separate cross sections of the lungs at 400× magnification
were assessed for each experimental group, with scores ranging
between 0 and 1 for each sample.

Real-Time Polymerase Chain
Reaction (qPCR)

Neonatal mice were euthanized 10 h after sepsis induction by CS
injection. Whole lungs were then harvested, flash frozen at −80°C,
and crushed over dry ice to a fine powder. Total RNA was extracted
from crushed tissue using TRIzol reagent (Invitrogren, Carlsbad).
Total RNA (2 µg) underwent reverse transcription using murine
Frontiers in Immunology | www.frontiersin.org

Statistical Analysis

Data are expressed as mean ± SEM and compared by one-way
analysis of variance (ANOVA) and the Student–Newman–Keuls
3
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test. For survival studies, Kaplan–Meier curves are presented and
groups were compared using the log-rank test. Differences in
values were considered significant if p < 0.05.

the neonates. We used the 30-h time point for pretreatment as the
earliest possible when considering technical feasibility and mothers’ behavior (22). Ten hours after CS injection blood was collected and serum cytokine levels were measured. Vehicle-treated
septic neonates demonstrated a significant increase in serum
levels of the proinflammatory cytokines IL-6 (48 ± 3 ng/ml) and
IL-1β (310 ± 23 pg/ml) compared to sham pups (undetectable,
Figures 1A,B). Treatment with KRN shortly after sepsis induction
resulted in a worsening of systemic inflammation, with a further
elevation in IL-6 levels (58 ± 5 ng/ml) and a significant increase
in IL-1β levels (439 ± 27 pg/ml, Figures 1A,B). Thirty-hour KRN

RESULTS
Timing of KRN Treatment Affects Systemic
Inflammation in Neonatal Sepsis

We first determined the effect of KRN treatment within 1 h after
(0 h K) or 30 h prior to (−30 h K) CS injection on inflammation in

Figure 1 | Effect of KRN treatment timing on inflammation and pulmonary injury in septic neonatal mice. Neonatal C57BL/6 pups received KRN (0.2 µg/g BW) or
vehicle (2.5% dimethyl sulfoxide in PBS) intraperitoneal (i.p.) within 1 h after (0 h K) or 30 h prior to (−30 h K) sepsis induction. Sepsis was induced by i.p. injection
of cecal slurry (0.9 mg/g BW); serum and lungs were harvested 10 h later. Serum levels of (A) IL-6 and (B) IL-1β were measured by enzyme-linked immunosorbent
assay. The mRNA levels of (C) IL-6, (D) IL-1β, (E) KC, and (F) MIP-2 in the lungs were determined by qPCR. (G) Shown are representative hematoxylin and
eosin-stained sections of the lung from sham, vehicle-treated, 0 h KRN-treated and −30 h KRN-treated animals at 200× magnification. (H) Histologic lung injury
score was calculated for each group, with a maximum possible score of 1. Data expressed as mean ± SEM (n = 6–8 per group) and compared by one-way
analysis of variance (*p < 0.05 vs. Sham, #p < 0.05 vs. Vehicle, Ψp < 0.05 vs. 0 h K).
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CD3 antibodies and PE-labeled α-GalCer-loaded CD1d tetramer
antibodies to identify iNKT cells (Figure 2B). We then looked
at the level of activation of this subset using APC/Cy7-labeled
CD69 antibodies (Figure 2C).
The frequency of CD69-positive iNKT cells in the liver increased from 14.4 ± 0.8% in untreated controls to a peak of
27.6 ± 2.2% 5 h after KRN administration (Figure 2D). We also
measured serum levels of IFN-γ, which is released by activated
iNKT cells (27). Serum level of IFN-γ in control pups was
3.8 ± 1.1 pg/ml and reached a peak of 38.4 ± 12.2 pg/ml at 10 h
after KRN administration (Figure 2D). Both CD69 expression
and IFN-γ serum levels returned to near baseline levels at 30 h
(15.0 ± 1.2% and 13.2 ± 4.2 pg/ml, respectively, Figures 2D,E).
These data reveal the activated status of iNKT cells in the neonates with KRN treatment before they were subjected to sepsis
induction.

pretreatment, on the other hand, significantly reduced serum
levels of IL-6 compared to vehicle- and 0 h KRN-treated septic
neonatal mice (34 ± 6 ng/ml, Figure 1A). However, not much
change in IL-1β levels with KRN pretreatment compared to the
vehicle (Figure 1B).

Timing of KRN Treatment Affects
Pulmonary Inflammation and
Injury in Neonatal Sepsis

Lung injury is an important contributor to morbidity and mortality in neonatal sepsis (23, 24). We next examined the effect
of KRN treatment timing on pulmonary inflammation in our
polymicrobial sepsis model. Ten hours after sepsis induction,
expression of IL-6 and IL-1β as well as the neutrophil chemoattractants KC and MIP-2 in the lungs of neonatal mice were measured. Vehicle-treated septic neonates demonstrated a significant
increase in IL-6, IL-1β, KC, and MIP-2 expression compared to
sham (144-, 56-, 127-, and 143-fold, respectively; Figures 1C–F).
Furthermore, 0 h KRN treatment exacerbated this inflammation
with significant increases in IL-6, KC, and MIP-2 expression
compared to the vehicle-treated pups (400-, 231-, and 308-fold
of sham, respectively; Figures 1C,E,F). In contrast, −30 h KRN
treatment attenuated inflammation in the lungs as it had systemically, with significant decreases in expression of IL-6, IL-1β, and
KC compared to vehicle-treated septic mice (15-, 30-, and 37-fold
of sham, respectively; Figures 1C–E).
We next sought to correlate the differential effect of KRN
treatment timing on systemic and pulmonary inflammation
with lung injury at the histologic level. Representative sections
of the lungs from each group are shown in Figure 1G. Sham pups
had a mean histologic injury score of 0.30 ± 0.03 (Figure 1H),
based on the American Thoracic Society assessment with the
maximum score of one. This was significantly increased in
vehicle-treated pups to 0.61 ± 0.04 (Figure 1H). Pups treated
with KRN after sepsis induction demonstrated a similar level
of histologic lung injury to vehicle-treated pups (0.64 ± 0.04,
Figure 1H). Consistent with our findings of decreased systemic
levels of proinflammatory cytokines and decreased cytokine and
chemokine expression in the lungs, −30 h KRN-treated pups
demonstrated an attenuation of histologic lung injury compared
to vehicle- and 0 h KRN-treated septic neonates (0.49 ± 0.04,
Figure 1H).

Timing of KRN Treatment Affects iNKT
Cell Activation Status in Neonatal Sepsis

After determining the kinetic response of iNKT cells to KRN
administration, we next examined the effect of KRN treatment
timing during sepsis on iNKT cells. We isolated the cells from the
livers of sham and septic pups with vehicle and 0 h KRN treatments
at 10 h after CS injection and analyzed them by flow cytometry.
Vehicle-treated septic pups demonstrated a significant increase in
the frequency of CD69 expression on hepatic iNKT cells compared
to sham pups (23.9 ± 2.3 vs. 16.1 ± 1.7%), and this was further
increased in 0 h KRN-treated pups (26.1 ± 3.2%, Figures 3A,B). In
addition, vehicle-treated pups had a significant increase in serum
levels of IFN-γ 10 h after CS injection compared to sham pups
(1.3 ± 0.7 vs. 474.7 ± 73.6 pg/ml), which was further increased
in the 0 h KRN-treated pups (1,027.8 ± 144.0 pg/ml, Figure 3C).
In a 7-day survival study, the 0 h KRN-treated septic pups died
earlier than the vehicle-treated group (Figure 3D).
Conversely, septic pups that received −30 h KRN treatment
demonstrated a decrease in CD69 expression on hepatic iNKT cells
compared to vehicle-treated pups (16.2 ± 1.6 vs. 23.9 ± 2.2%,
Figures 4A,B), as well as a decrease in systemic levels of IFN-γ
(209.1 ± 70.3 vs. 474.7 ± 73.6 pg/ml, Figure 4C). This redu-
ction in iNKT cell activation corresponds to the previously
mentioned reduction in systemic and pulmonary inflammation
and histologic lung injury. In addition, −30 h KRN treatment
resulted in a remarkable 38% survival rate at 7 days compared to
no survival in the vehicle-treated group (p = 0.026, log-rank test;
Figure 4D).

Kinetic Analysis of iNKT Cell Activation
in Neonatal Mice

Given the differential effects of KRN treatment at different treatment time points in neonatal sepsis, we next determined the
activation kinetics of neonatal iNKT cells after KRN administration. It has been reported that iNKT cells are abundantly found
in the liver of adult mice (13, 25, 26). As such, we examined the
activation status of hepatic iNKT cells at 1, 5, 10, 20, and 30 h in
healthy neonatal mice after KRN treatment by measuring CD69
expression using flow cytometry. The total hepatic lymphocyte
population was gated by FSC and SSC characteristics (Figure 2A).
We further excluded doublets and dead cells as described in the
Section “Materials and Methods.” We then used FITC-labeled

Frontiers in Immunology | www.frontiersin.org

The Protective Effect of KRN Pretreatment
Is Dependent on CD1d

We next wished to confirm that the protective effect seen with 30 h
KRN pretreatment was mediated through CD1d. First, we looked
at the effect of −30 h KRN treatment on systemic inflammation
in septic CD1d KO neonatal mice. At 10 h after sepsis induction, there was no difference in levels of the proinflammatory
cytokines IL-6 or IL-1β between vehicle- and KRN-pretreated
pups (41 ± 13 vs. 39 ± 5 ng/ml and 162 ± 58 vs. 199 ± 55 pg/ml,
respectively; Figures 5A,B). On qPCR analysis, there was no

5
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Figure 2 | Kinetic analysis of KRN treatment on hepatic invariant natural killer T (iNKT) cell activation in neonatal mice. Serum and liver from C57BL/6 pups
received KRN (0.2 µg/g BW) intraperitoneal were harvested at 1, 5, 10, 20, and 30 h after KRN administration or sham. Liver was dissociated through a 70-µm
strainer to isolate hepatocytes, followed by staining and flow cytometry analysis. A representative sample showing flow cytometry gating strategy is shown.
(A) Total cells isolated from the liver were gated for the live lymphocyte population based on forward scatter (FSC) and side scatter (SSC) characteristics.
(B) The iNKT cell population was then identified by gating for the FITC-CD3 and PE-CD1d tetramer double-positive cell population. (C) Flow cytometric analysis
of surface CD69 expression on the gated hepatic iNKT cells. Shaded area indicates negative control. (D) Flow cytometric analysis of surface CD69 expression on
gated hepatic iNKT cells at each time point. (E) Interferon (IFN)-γ levels in the serum were measured by enzyme-linked immunosorbent assay at each time point.
Data expressed as mean ± SEM (n = 6–16 per group) and compared by one-way analysis of variance (*p < 0.05 vs. Ctrl, #p < 0.05 vs. 1 h, ψp < 0.05 vs. 5 h).

Kinetic Analysis of KRN Treatment on
Serum Cytokine Levels in Neonatal Mice

statistical difference in expression of IL-6 or IL-1β in the lungs
of vehicle- and KRN-pretreated septic CD1d KO pups (54- vs.
86-fold and 61- vs. 53-fold of sham, respectively; Figures 5C,D),
nor was there a difference in expression of the neutrophil chemo
attractants KC and MIP-2 between the two groups (255- vs. 238fold and 399- vs. 396-fold of sham, respectively; Figures 5E,F).
CD1d KO sham pups had histologic lung injury scores of
0.30 ± 0.03, similar to C57BL/6 sham pups (Figure 5G). Both vehicleand −30 h KRN-treated septic CD1d KO neonates demonstrated
increased lung injury compared to sham pups, although there was
no statistical difference in injury score between the two septic groups
(0.58 ± 0.04 and 0.52 ± 0.04, respectively; Figures 5G–J). There was
also no difference in 7-day survival between KRN-pretreated and
vehicle-treated CD1d KO pups (Figure 5K).

Frontiers in Immunology | www.frontiersin.org

Activated iNKT cells release several cytokines and affect many
other types of immune cells (27). We next examined whether
a change in cytokine expression profile is associated with the
protective effect of 30 h KRN pretreatment on inflammation,
lung injury, and survival in neonatal sepsis. We utilized a
multi-analyte ELISArray to measure the relative levels of various cytokines in the serum of neonatal mice at 1, 5, 10, 20, and
30 h after KRN treatment. Due to the limited volume of blood
that could be drawn from each neonate, we pooled samples
from neonates at each time point (5–10 samples per group) to
perform the cytokine array analysis. As shown in Figure S1 in
Supplementary Material, most notably, there was a slight increase
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Figure 3 | Effect of 0 h KRN treatment on invariant natural killer T (iNKT) cell activation and survival in septic neonatal mice. Sepsis was induced in neonatal
C57BL/6 pups by intraperitoneal (i.p.) injection of cecal slurry (CS, 0.9 mg/g BW). Pups then received KRN (0.2 µg/g BW) or vehicle (2.5% dimethyl sulfoxide in
PBS) i.p. within 1 h. Serum and liver were harvested 10 h later. (A) Representative histogram of CD69 expression on hepatic iNKT cells. (B) Flow cytometric analysis
of surface CD69 expression on gated hepatic iNKT cells. (C) Interferon (IFN)-γ levels in the serum were measured by enzyme-linked immunosorbent assay. Data
expressed as mean ± SEM (n = 6–9 per group) and compared by one-way analysis of variance (*p < 0.05 vs. Sham, #p < 0.05 vs. Vehicle). (D) Another set of
pups received the same dose of KRN or vehicle within 1 h after sepsis induction by CS (0.175 mg/g BW) and survival was monitored for seven days (n = 17 per
group, p = 0.129, log-rank test).

in IL-2, a cytokine implicated in lymphocyte proliferation and
type I immunity (Th1) at 5 h after KRN administration. This
corresponds to the time point at which peak frequency of CD69
expression on iNKT cells in the neonatal liver was seen. Then, at
the protective 30-h time point, the absorbance value for TGF-β1,
considered Th2- or Th17-associated depending on the cytokine
milieu, reached three times that of the control sample. Additional
Th1- (IL-6, IL-12, TNF-α), Th2- (IL-4, IL-5, IL-10, IL-13), and
Th17- (IL-17A, IL-23) associated cytokines were also analyzed.
In addition to TGF-β1, but to a lesser degree, IL-4 was increased
at 30 h relative to control levels. TNF-α, IL-6, IL-10, IL-17A, and
IL-23 showed smaller increases at 30 h relative to control, while
IL-2, IL-12, IL-5, and IL-13 were near baseline levels.

TGF-β1 (0.05 µg/g BW) or vehicle (PBS containing 0.8 mM HCl)
i.p. within 1 h prior to CS injection. Ten hours after sepsis induction, vehicle-treated pups demonstrated a significant increase in
serum levels of IL-6 and IL-1β compared to sham pups (55.9 ± 4.2
vs. 0.1 ± 0.1 ng/ml and 377.2 ± 42.6 vs. 4.6 ± 2.6 pg/ml, respectively; Figures 6A,B). TGF-β1 treatment did not significantly
attenuate systemic levels of IL-6 (50.4 ± 6.9 ng/ml, Figure 6A),
but did result in a significant decrease in systemic levels of IL-1β
compared to vehicle treatment (248.1 ± 32.0 pg/ml, Figure 6B).
Turning our attention to pulmonary inflammation, on qPCR
analysis there was an eight-fold increase in IL-6 expression and a
17-fold increase in IL-1β expression in vehicle-treated septic pups
compared to sham pups (Figures 6C,D). TGF-β1 significantly
decreased IL-6 and IL-1β expression in the lungs to just five- and
eight-fold of sham, respectively (Figures 6C,D). KC and MIP-2
expression were also increased in the lungs of vehicle-treated
septic pups compared to sham (72- and 173-fold, respectively),
and were attenuated in the TGF-β1-treated group (37- and 132fold, respectively, Figures 6E,F).

Effect of TGF-β1 Administration on
Inflammation in Neonatal Sepsis

After identifying a marked increase in serum TGF-β1 at 30 h after
KRN treatment, we further determined whether it played a role
in protecting neonates against sepsis. Neonatal mice received

Frontiers in Immunology | www.frontiersin.org
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Figure 4 | Effect of −30 h KRN treatment on invariant natural killer T (iNKT) activation cell activation and survival in septic neonatal mice. Neonatal C57BL/6
pups received KRN (0.2 µg/g BW) or vehicle (2.5% dimethyl sulfoxide in PBS) intraperitoneal (i.p.) 30 h prior to (−30 h K) sepsis induction. Sepsis was then
induced by i.p. injection of cecal slurry (CS, 0.9 mg/g BW). Serum and liver were harvested 10 h later. (A) Representative histogram of CD69 expression on
hepatic iNKT cells. (B) Flow cytometric analysis of surface CD69 expression on gated hepatic iNKT cells. (C) Interferon (IFN)-γ levels in the serum were measured
by enzyme-linked immunosorbent assay. Data expressed as mean ± SEM (n = 5–9 per group) and compared by one-way analysis of variance (*p < 0.05 vs.
Sham, #p < 0.05 vs. Vehicle). (D) Another set of pups received the same dose of KRN or vehicle 30 h prior to sepsis induction by CS (0.175 mg/g) and survival was
monitored for 7 days (n = 15–16 per group, *p = 0.026 vs. Vehicle, log-rank test).

Effect of TGF-β1 Administration on
Lung Injury in Neonatal Sepsis

KO neonatal mice. Contrary to the three-fold increase seen in
wild-type mice, there was no change in relative levels of TGF-β1
in CD1d KO mice at 30 h after KRN treatment (Figure S2 in
Supplementary Material). In addition, the change in several
cytokines in the wild-type neonatal mice was diminished in the
CD1d KO neonatal mice following KRN stimulation. This finding
further supports that activation of iNKT cells by KRN is mediated
by CD1d.

Given the clear reduction in systemic and pulmonary inflammation seen with TGF-β1 treatment in septic neonates, we then
examined the effect of this treatment on lung injury. Representative
H&E-stained sections from sham, vehicle- and TGF-β1-treated
pups are show in Figures 6G–I. Sham pups demonstrated a mean
histologic injury score of 0.14 ± 0.03 (Figure 6J). This score was
significantly increased to 0.63 ± 0.03 in vehicle-treated septic
pups, while TGF-β1-treated pups had significantly attenuated
histologic lung injury with a mean score of 0.46 ± 0.04 (Figure 6J).

DISCUSSION
In this study, we have demonstrated that treatment of neonatal
mice with the α-GalCer analog KRN7000 at the time of sepsis
induction by CS results in worsening of systemic and pulmonary
inflammation and histologic lung injury and accelerates mortality. In contrast, 30-h KRN pretreatment reduces systemic and
pulmonary inflammation, decreases histologic lung injury, and
improves survival in neonatal sepsis. We have further conducted
a 30-h kinetic analysis of neonatal iNKT cell activation and serum

Effect of KRN Treatment on Serum
Cytokine Levels in CD1d KO
Neonatal Mice

To further validate whether elevation of TGF-β1 after KRN treatment was mediated by CD1d, we performed the multi-analyte
ELISArray in the serum of control and KRN-treated CD1d
Frontiers in Immunology | www.frontiersin.org
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Figure 5 | Effect of −30 h KRN treatment on inflammation, pulmonary injury, and survival in septic CD1d knockout (KO) neonatal mice. Neonatal CD1d KO
pups received KRN (0.2 µg/g BW) or vehicle (2.5% dimethyl sulfoxide in PBS) intraperitoneal (i.p.) 30 h prior to sepsis induction. Sepsis was induced by i.p.
injection of cecal slurry (CS) (0.9 mg/g BW); serum and lungs were harvested 10 h later. Serum levels of (A) IL-6 and (B) IL-1β were measured by enzyme-linked
immunosorbent assay. The mRNA levels of (C) IL-6, (D) IL-1β, (E) keratinocyte chemoattractant, and (F) macrophage inflammatory protein-2 in the lungs were
determined by qPCR. (G–I) Shown are representative hematoxylin and eosin-stained sections of the lung from (G) sham, (H) vehicle-, and (I) −30 h KRN-treated
mice at 200× magnification. (J) Histologic lung injury score was calculated for each group with a maximum possible score of 1. Data expressed as mean ± SEM
(n = 6–8 per group) and compared by one-way analysis of variance (*p < 0.05 vs. Sham). (K) Another set of pups received the same dose of KRN or vehicle 30 h
prior to sepsis induction by CS (0.175 mg/g) and survival was monitored for 7 days (n = 17 per group, p = 0.667, log-rank test).

levels of several cytokines after KRN treatment. We have demon
strated that KRN’s protective effect is mediated by CD1d. We have
identified an increase in serum levels of TGF-β1 in neonates at
30 h after KRN stimulation. Finally, we have demonstrated that
administration of TGF-β1 attenuates systemic and pulmonary
inflammation and lung injury in neonatal mice, establishing a
mechanism through which KRN pretreatment exerts its protective effect.
We have shown that the timing of iNKT cell activation by
KRN critically affects outcomes in a neonatal model of poly
microbial sepsis. When given at the time of sepsis induction
by CS, KRN worsened injury. This is in line with a CS sepsis
model in adult mice, in which KRN treatment did not improve
survival relative to vehicle-treated controls when given within
20 min of CS injection (28). However, in an endotoxemia model
Frontiers in Immunology | www.frontiersin.org

in adult mice, KRN treatment increased survival, reduced serum
levels of AST and ALT, and protected mice from BW loss when
administered within 2 h before or after lipopolysaccharide (LPS)
challenge (29). Of note, these mice were pre-challenged with
low dose LPS 24 h before the second LPS administration. Such
discrepancy in outcomes suggests that the effect of KRN treatment is dependent on the type of infection. Another potential
factor that may contribute to varying outcomes between 0 h and
−30 h treatment groups is the developmental stage of iNKT cells.
Recognition of CD1d-loaded endogenous lipid antigen(s) on
CD4/CD8-double-positive (DP) thymocytes with interactions
between signaling lymphocyte activation molecule (SLAM)
family members is essential for the development of iNKT cells.
After differentiating into different iNKT cell subsets in the
thymus, these cells then distribute in peripheral organs (30).
9
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Figure 6 | Effect of transforming growth factor (TGF)-β1 administration inflammation and pulmonary injury in septic neonatal mice. Neonatal C57BL/6 pups
received recombinant mouse TGF-β1 (0.05 µg/g BW) or vehicle (PBS containing 0.8 mM HCl) intraperitoneal (i.p.) 1 h prior to sepsis induction. Sepsis was induced
by i.p. injection of cecal slurry (0.9 mg/g BW); serum and lungs were harvested 10 h later. Serum levels of (A) IL-6 and (B) IL-1β were measured by enzyme-linked
immunosorbent assay. The mRNA levels of (C) IL-6, (D) IL-1β, (E) keratinocyte chemoattractant, and (F) macrophage inflammatory protein-2 in the lungs were
determined by qPCR. (G–I) Shown are representative hematoxylin and eosin-stained sections of the lung from (G) sham, (H) vehicle-, and (I) TGF-β1-treated
mice at 200× magnification. (J) Histologic lung injury score was calculated for each group with a maximum possible score of 1. Data expressed as mean ± SEM
(n = 7–8 per group) and compared by one-way analysis of variance (*p < 0.05 vs. Sham, #p < 0.05 vs. Vehicle).

The role of SLAM signaling on changes in cytokine levels at
different time points after KRN treatment needs further investigation. Also, it will be interesting to look at differences in treatment timing over age ranges of hours rather than days to further
elucidate the effect of immune system maturation on iNKT cell
activation in the future.
In contrast to what was seen in the KRN posttreatment experiment, KRN pretreatment 30 h before CS injection resulted in a
reduction in systemic and pulmonary inflammation and histologic
lung injury. Furthermore, we demonstrated a significant increase
in 7-day survival to 38 from 0% survival in the vehicle-treated
group. Likewise, adult mice that received KRN pretreatment
6 to 12 days before LPS injection also show reduced organ injury
and improved survival (31). However, in our neonatal model,
30-h KRN pretreatment was sufficient to show the protective

Frontiers in Immunology | www.frontiersin.org

effect, while pretreatment at least 72 h prior to LPS injection was
required to see a protective effect in adult mice. Due to the age of
the neonates used in our study, we cannot extend the time of KRN
pretreatment further to test whether earlier KRN treatment will
provide better protection. It has been reported that administration of KRN to pregnant mice induces abortion through decidual
iNKT cell activation (32). To our knowledge there has not been a
study of KRN pretreatment in a polymicrobial sepsis model such
as CS or cecal ligation and puncture in adult animals; such study
is warranted in order to more directly compare the response of
neonatal and adult iNKT cells to KRN pretreatment in sepsis.
Nevertheless, the benefits demonstrated with KRN pretreatment
in the neonate highlight the potential of modulating the neonatal
immune system, including via iNKT cell activation, for prophylactic benefit in populations particularly at risk for sepsis (i.e.,
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state (35). Given that in our kinetic analysis we saw increases in
both frequency of CD69 expression and IFN-γ levels at five to
10 h after KRN administration, and our understanding of IFN-γ
as a proinflammatory cytokine, this synergistically detrimental
effect at 10 h following sepsis induction and KRN administration
is not surprising.
In our kinetic analysis, CD69 expression had returned to
baseline by the 30-h time point, as had IFN-γ levels in the
serum in neonates. Therefore, at the time of CS injection in
the 30 h KRN-pretreated neonates, their iNKT cells were not
in the activated state. However, we still observed a relative and
significant decrease in both frequency of CD69 expression on
iNKT cells and in serum IFN-γ levels in the 30 h KRN-pretreated
neonates, compared to the vehicle. It is possible that KRNstimulated iNKT cells develop tolerance that blunts the secondary insult by CS injection. In addition, activated iNKT cells
may stimulate other immune cells to protect against the insult
of CS injection 30 h later. In our multi-analyte ELISArray
study, we observed a change in several cytokines in the serum
of neonates 30 h after KRN stimulation, which further supports
the notion that other immune cells are activated after iNKT cell
stimulation.
KRN is a synthetic α-GalCer analog and CD1d ligand. We
next determined whether KRN was acting through this pathway
rather than an alternative one to affect outcomes in neonatal sepsis. In order to study this, we utilized CD1d KO mice. These mice
harbor deletions of the CD1d1 and CD1d2 loci, which prohibit
the normal development of NKT cells. KRN was administered
to CD1d KO neonates 30 h prior to sepsis induction by CS, as
had been done in the C57BL/6 wild-type neonates. Remarkably,
10 h after sepsis induction, there were no differences in serum
levels of IL-6 or IL-1β, or in fold induction of IL-6, IL-1β, KC,
or MIP-2 mRNA expression in the lungs between vehicle- and
KRN-pretreated CD1d KO pups, in contrast to what was seen
in the wild-type neonates. In addition, while sepsis induced
histologic lung injury in these pups compared to the sham, there
was not a protective effect in the KRN-pretreated CD1d KO
pups. The protective effect of KRN pretreatment was abrogated
in the KO animals, confirming our suspicion that CD1d mediates
KRN’s effect. This is consistent with previous findings in adult
animals that KRN administration in vivo resulting in the activation of NKT cells is lost in CD1d-deficient mice (36). To identify
potential cytokines mediating this protective effect, we next used
a multi-analyte ELISArray to assess relative cytokine levels in the
serum at various time points for 30 h after KRN administration.
At 5 h, there was a modest but noticeable increase in the Th1associated proinflammatory cytokine IL-2. This is consistent
with our initial quantitative analysis of serum levels of IFN-γ,
another Th1-associated cytokine, which showed a peak at 10 h
after KRN administration, as well as our flow cytometric analysis
of hepatic iNKT cells, which demonstrated increased frequency
of CD69 expression at 5 h after KRN administration. Whether
an overall Th1 phenotype in the immune response at five to 10 h
after KRN administration might contribute to the exacerbated
inflammation and accelerated mortality seen in the 0 h KRN
treatment group is an interesting possibility that warrants further
investigation.

premature and very low birth weight infants). Moreover, with the
observation of opposite effects between pre- and immediate posttreatment with KRN, it will be worthwhile to explore the effects
of delayed treatment (i.e., more than 1 h after CS injection) at
multiple time points following sepsis induction in neonates in
future studies.
To understand the effect of KRN treatment on iNKT cells,
we monitored the activation status of iNKT cells in neonatal
mice for 30 h after treatment. We focused on the hepatic subset
of iNKT cells because of its abundance relative to other compartments. It is estimated that NKT cells compromise 30% of
the lymphoid population in the mouse liver, and up to 50% of
the hepatic lymphoid population in humans (25, 33). On the
other hand, iNKT cells make up only 1–2% of lymphocytes
in the mouse spleen and an estimated 0.1–0.2% of peripheral
blood T cells in humans (13). We found that frequency of the
activation marker CD69 expression in these hepatic iNKT cells
increased from a baseline level of 14% to a peak of 28% at 5 h
after KRN administration. Frequency of CD69 expression then
decreased to baseline levels at 30 h after KRN administration.
These findings correlated with serum levels of IFN-γ, a cytokine
secreted by iNKT cells as well as several downstream effector
cells after iNKT activation, which increased modestly after
KRN administration to a maximum of 38 pg/ml at 10 h. We
also measured IL-4 in the serum, but saw no significant increase
in levels compared to the control at any time point (data not
shown).
The kinetics of iNKT cell activation in neonates that we demonstrated here are different from those that have been reported
in adult mice. In response to KRN injection in adult mice,
NKT cells become activated within minutes to hours and express
activation markers including CD69 (27). Within 1 h of KRN
treatment IL-4 is produced by NKT cells, and this is followed
by an increase in IFN-γ production, which peaks at 24 h after
injection (27, 34). Given that we see a serum increase in IFN-γ
and iNKT cell activation at five to 10 h after KRN administration
in the neonates, contrary to the peak at 24 h in adult mice. In
addition, serum IL-4 levels in the neonates did not change during
any of the time points in our study. There may be an early increase
in IL-4 production in neonatal iNKT cells that is not captured in
our studies within 1 h.
The changes in iNKT cell activation and serum IFN-γ levels
5–10 h after KRN administration in healthy neonates correspond
to the exacerbated inflammatory response seen with 0 h KRN
treatment in septic neonates. In our sepsis model, vehicle-treated
animals demonstrated a significant increase in both frequency
of CD69 expression on iNKT cells and serum IFN-γ levels at
10 h after CS injection. With 0 h KRN treatment, there was an
increase in frequency of CD69 expression on iNKT cells and
a significant increase in serum IFN-γ levels compared to the
vehicle. IFN-γ plays a critical role in initiating and sustaining the
innate immune response to infection. Its production by natural
killer cells is important for controlling infection in the early
stages of the response, before the adaptive immune system has
been activated (35). In addition, CD4+ T cells exposed to IFN-γ
in the early phase of infection tend to differentiate into Th1 type
effector cells, rather than Th2 cells, leading to a proinflammatory
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At our protective 30-h time point, there was a marked increase
in serum TGF-β1 levels. TGF-β1 has been shown to regulate
multiple immune cell types. It inhibits aberrant T cell expansion,
inhibits myeloid proliferation, downregulates production of reactive oxygen species in myeloid cells, acts as a chemotactic factor
for monocytes, and negatively regulates the proinflammatory
NF-κB pathway (37). Considering the diverse protective effects
of TGF-β and our finding of elevated serum levels of TGF-β1
in neonatal mice 30 h after KRN administration, we then determined the effect of TGF-β1on septic neonates. In fact, we found
that recombinant murine TGF-β1 administered to C57BL/6
neonates 1 h prior to sepsis induction by CS decreased systemic
and pulmonary inflammation and decreased pulmonary injury
compared to vehicle. The beneficial effect of TGF-β1 administration has also been demonstrated in a neonatal rat model
of necrotizing enterocolitis (NEC), in which it reduced NEC
incidence and systemic inflammation in addition to protecting
the integrity of the gut epithelium (38). Similarly, in adult rats
with endotoxemia, TGF-β1 reduced inflammation and improved
survival (39).
To further confirm that TGF-β1 mediates the protective effect
of 30-h KRN pretreatment, we determined serum cytokine levels
in CD1d KO neonates at 30 h after KRN administration. Compared
to wild-type neonates, changes in most cytokine levels, especially
TGF-β1, were diminished in the KRN-stimulated CD1d KO neonates. As we have demonstrated, the protective effect of 30 h KRN
pretreatment is lost in the CD1d KO neonates. Taken together,
these results indicate that the elevation of serum TGF-β1 levels
contributes to the protective effect of KRN pretreatment in septic
neonates and is mediated through CD1d.
In this study, we observed an early Th1-biased response at 5 h
after KRN administration in neonatal mice, with increases in
serum levels of IL-2 and frequency of CD69 expression on hepatic
iNKT cells, followed at 10 h by an increase in serum IFN-γ levels.
At 30 h after KRN administration, on the other hand, hepatic
iNKT cell activation returned to baseline, as did levels of the
Th1-associated cytokines IL-2, IL-12, and IFN-γ. Most notably
increased at this time point was TGF-β1, which is alternately
described as a Th2- or Th17-associated cytokine, and possesses
many anti-inflammatory properties as outlined above.
Our data show increases in TGF-β1 and IL-6 in the serum of
neonatal mice 30 h after KRN administration, as well as in IL-17A
and IL-23. This profile is suggestive of a Th17-polarizing milieu.
Some LPS-negative α-proteobacteria (e.g., S. capsulata and
E. muris) possess cell wall glycosylceramides that serve as direct
targets for iNKT cells, and upon recognition of these targets,
iNKT cells are able to facilitate bacterial clearance and control
infection (40, 41). It has been speculated that iNKT cells may have
evolved to target such bacteria lacking TLR ligands (42). Given
that iNKT cells can evoke strong cytokine signaling cascades in
the absence of activation by TLR ligands, their activation may thus
offer a route for increased Th17 polarization in neonates. Th17
immunity is important for maintaining epithelial barrier function; in neonates with relatively impaired opsonization ability due
to complement insufficiency and reliance on maternal antibody
transmission, this may be critical in preventing translocation of
bacteria and evading lethal infection (43, 44).
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It is understood that upon activation iNKT cells present in
liver sinusoids arrest and exert various effector functions (13). In
contrast, after antigen exposure in the lungs, iNKT cells present
there appear to extravasate and exert their effector functions in
the surrounding parenchyma, rather than entering the circulation (13). This raises the important question as to whether or
not KRN’s effect on pulmonary inflammation and injury in our
sepsis model is the result of its action on iNKT cells resident
in the lungs or liver, and if iNKT cell populations in different
compartments respond similarly to antigen stimulation in the
neonate. In light of our experiments demonstrating a correlation
between hepatic iNKT cell activation, serum levels of proinflammatory cytokines, and lung injury, it seems likely that this lung
injury is the result of systemic IFN-γ release. However, there may
be an additional effect of activated iNKT cells within the lungs,
and an investigation into the response of iNKT cells within different compartments to KRN administration in the neonate is
warranted in the future.
An important limitation of our cytokine array analysis is
the use of pooled serum samples. This approach was useful to
broadly identify potential mediators in response to iNKT cell
activation, and led us to examine the effects of TGF-β1 on septic
neonates. Although the change in cytokine levels observed in
the array study could not be adequately analyzed statistically to
lend itself to a clear conclusion, the results provide guidance for
future studies. In addition, we have used a one-way ANOVA to
analyze the statistical difference among the four groups including
sham, vehicle, 0 h, and −30 h treatment groups in Figure 1. In the
future, when we conduct KRN administration at multiple time
points surrounding sepsis onset to study the interaction between
time and treatment, the sample size of each group will need to
increase in order to have sufficient statistical power to perform a
two-way ANOVA analysis.
Herein, we have established for the first time the response of
neonatal iNKT cells to a CD1d ligand, and explored the effect of
activation of neonatal iNKT cells at multiple time points around
sepsis induction. We have confirmed that the protective effect
of iNKT cell pre-activation is mediated by the CD1d molecule
through a systemic increase in TGF-β1. Future research in this
area should aim to shed light on differences in iNKT subsets resident in different compartments and on generating pharmacologic
agents that may be used to polarize these cells toward a protective
phenotype in the setting of neonatal infection.
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